Axonics® to Present at Upcoming Investor Conferences - Aug. 27, 2019

August 27, 2019 |

2 min read

Axonics Modulation Technologies, Inc. announced that members of the senior management team will present at the following upcoming investor conferences and will be available for meetings with institutional investors

Aug. 27, 2019 10:00 UTC

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing a novel implantable Sacral Neuromodulation (“SNM”) device for the treatment of urinary and bowel dysfunction, today announced that members of the senior management team will present at the following upcoming investor conferences and will be available for meetings with institutional investors:

Raymond W. Cohen, Chief Executive Officer, is scheduled for a fireside chat at the Wells Fargo Healthcare Conference on Thursday, September 5, at 2:30 pm EDT at the Westin Copley Place in Boston.

Cohen is also scheduled for a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, at 8:45 am EDT at the Grand Hyatt in New York City.

To access the live webcast of the fireside chats at the aforementioned conferences, please visit the Events & Presentations page of the Investors section of the Company’s website at ir.axonicsmodulation.com. A replay of the webcasts will be available shortly after the conclusion of the fireside chats and will be archived on the Company’s website for 90 days.

About Axonics Modulation Technologies, Inc.

Axonics, based in Irvine, CA, has developed and is commercializing a novel implantable SNM device for patients with urinary and bowel dysfunction. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe. Another estimated 40 million adults are reported to suffer from fecal incontinence. SNM therapy is a well-established treatment that has been widely used and reimbursed in the U.S. and Europe for the past two decades. The Axonics r-SNM System is the first rechargeable SNM system approved for sale in Europe, Canada and Australia, and the first SNM system to gain CE mark for full-body MRI conditional labeling. Premarket approval for the r-SNM System is currently pending with the U.S. FDA. For more information, visit the Company’s website at www.axonicsmodulation.com.